Actavis launches Ondansetron tablets in the U.S.

Actavis Group has announced that it has launched Ondansetron Tablets in the U.S. Actavis will market the product under an agreement with Natco Pharma Limited. Distribution of the product will commence immediately.

Ondansetron hydrochloride tablets, the generic equivalent of GlaxoSmithKline's Zofran(R) tablets, will be available in 4 mg and 8 mg strengths. Ondansetron hydrochloride tablets are indicated for prevention of nausea and vomiting caused by cancer chemotherapy, radiation therapy and surgery.

Annual sales of Ondansetron hydrochloride tablets in the U.S. were approximately US$746 million for the twelve months ending March 2007 according to IMS Health data.

http://www.actavis.com/

Comments

The opinions expressed here are the views of the writer and do not necessarily reflect the views and opinions of News Medical.
Post a new comment
Post

While we only use edited and approved content for Azthena answers, it may on occasions provide incorrect responses. Please confirm any data provided with the related suppliers or authors. We do not provide medical advice, if you search for medical information you must always consult a medical professional before acting on any information provided.

Your questions, but not your email details will be shared with OpenAI and retained for 30 days in accordance with their privacy principles.

Please do not ask questions that use sensitive or confidential information.

Read the full Terms & Conditions.